| Code | CSB-RA011665MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to tocilizumab, targeting the interleukin-6 receptor (IL6R). IL6R is a critical component of the IL-6 signaling pathway, which plays a central role in inflammatory and immune responses. Upon IL-6 binding, IL6R forms a complex with the signal-transducing component gp130, triggering downstream JAK-STAT signaling cascades that regulate acute phase responses, B-cell differentiation, and T-cell activation. Dysregulated IL-6/IL6R signaling is implicated in numerous pathological conditions, including rheumatoid arthritis, cytokine release syndrome, systemic juvenile idiopathic arthritis, and various inflammatory disorders.
Tocilizumab, the reference therapeutic antibody, is a humanized IgG1 monoclonal antibody that binds to both soluble and membrane-bound forms of IL6R, effectively blocking IL-6-mediated signaling. This biosimilar antibody serves as a valuable research tool for investigating IL-6/IL6R pathway mechanisms, studying inflammatory disease models, evaluating cytokine signaling networks, and supporting preclinical therapeutic development. It enables researchers to explore the biological consequences of IL6R blockade in various experimental systems.
There are currently no reviews for this product.